Literature DB >> 28587376

Clinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet allocation analysis.

Yee Suk Kim1, Sungin Lee2, Nansu Zong3, Jimin Kahng4.   

Abstract

The present study aimed to investigate differences in prognosis based on human papillomavirus (HPV) infection, persistent infection and genotype variations for patients exhibiting atypical squamous cells of undetermined significance (ASCUS) in their initial Papanicolaou (PAP) test results. A latent Dirichlet allocation (LDA)-based tool was developed that may offer a facilitated means of communication to be employed during patient-doctor consultations. The present study assessed 491 patients (139 HPV-positive and 352 HPV-negative cases) with a PAP test result of ASCUS with a follow-up period ≥2 years. Patients underwent PAP and HPV DNA chip tests between January 2006 and January 2009. The HPV-positive subjects were followed up with at least 2 instances of PAP and HPV DNA chip tests. The most common genotypes observed were HPV-16 (25.9%, 36/139), HPV-52 (14.4%, 20/139), HPV-58 (13.7%, 19/139), HPV-56 (11.5%, 16/139), HPV-51 (9.4%, 13/139) and HPV-18 (8.6%, 12/139). A total of 33.3% (12/36) patients positive for HPV-16 had cervical intraepithelial neoplasia (CIN)2 or a worse result, which was significantly higher than the prevalence of CIN2 of 1.8% (8/455) in patients negative for HPV-16 (P<0.001), while no significant association was identified for other genotypes in terms of genotype and clinical progress. There was a significant association between clearance and good prognosis (P<0.001). Persistent infection was higher in patients aged ≥51 years (38.7%) than in those aged ≤50 years (20.4%; P=0.036). Progression from persistent infection to CIN2 or worse (19/34, 55.9%) was higher than clearance (0/105, 0.0%; P<0.001). In the LDA analysis, using symmetric Dirichlet priors α=0.1 and β=0.01, and clusters (k)=5 or 10 provided the most meaningful groupings. Statistical and LDA analyses produced consistent results regarding the association between persistent infection of HPV-16, old age and long infection period with a clinical progression of CIN2 or worse. Therefore, LDA results may be presented as explanatory evidence during time-constrained patient-doctor consultations in order to deliver information regarding the patient's status.

Entities:  

Keywords:  atypical squamous cells of undetermined significance; high-risk lesions; human papillomavirus; latent Dirichlet allocation; patient-doctor communication

Year:  2017        PMID: 28587376      PMCID: PMC5450758          DOI: 10.3892/etm.2017.4295

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

1.  Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results.

Authors:  Thomas C Wright; Mark H Stoler; Abha Sharma; Guili Zhang; Catherine Behrens; Teresa L Wright
Journal:  Am J Clin Pathol       Date:  2011-10       Impact factor: 2.493

2.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

3.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.

Authors:  D Solomon; M Schiffman; R Tarone
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

4.  Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions.

Authors:  G-Y Lee; S-M Kim; S-Y Rim; H-S Choi; C-S Park; J-H Nam
Journal:  Int J Gynecol Cancer       Date:  2005 Jan-Feb       Impact factor: 3.437

Review 5.  Management of stage IA cervical carcinoma.

Authors:  M Morris
Journal:  J Natl Cancer Inst Monogr       Date:  1996

Review 6.  Susceptibility to cervical cancer: an overview.

Authors:  Antonio Carlos de Freitas; Ana Pavla Almeida Diniz Gurgel; Bárbara Simas Chagas; Eliane Campos Coimbra; Carolina Maria Medeiros do Amaral
Journal:  Gynecol Oncol       Date:  2012-04-04       Impact factor: 5.482

7.  Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.

Authors:  Philip E Castle; Diane Solomon; Mark Schiffman; Cosette M Wheeler
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

8.  Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix.

Authors:  M Morris; M F Mitchell; E G Silva; L J Copeland; D M Gershenson
Journal:  Gynecol Oncol       Date:  1993-11       Impact factor: 5.482

9.  Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis.

Authors:  Nam Hoon Cho; Hee Jung An; Jeongmi Kim Jeong; Suki Kang; Jae Wook Kim; Young Tae Kim; Tchan Kyu Park
Journal:  Am J Obstet Gynecol       Date:  2003-01       Impact factor: 8.661

10.  [Clinical efficacy of HPV DNA chip test in the era of HPV vaccination: 1,211 cases, a single institution study].

Authors:  Jimin Kahng; Hee Jeong Lee
Journal:  Korean J Lab Med       Date:  2008-02
View more
  1 in total

1.  Mining news media for understanding public health concerns.

Authors:  Maryam Zolnoori; Ming Huang; Christi A Patten; Joyce E Balls-Berry; Somaieh Goudarzvand; Tabetha A Brockman; Elham Sagheb; Lixia Yao
Journal:  J Clin Transl Sci       Date:  2019-10-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.